The effect of NCX4016 [2-acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester] on the consequences of ischemia and reperfusion in the streptozotocin diabetic rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 3, 2006, Pages 1107-1114

  Burke, S G ^a   Wainwright, C L ^b   Vojnovic, I ^c   Warner, T ^c   Watson, D G ^a   Furman, B L ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b ROBERT GORDON UNIVERSITY   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; GLUCOSE; INSULIN; ISOPHANE INSULIN; MACROGOL; NITRIC OXIDE; PENTOBARBITAL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; INCIDENCE; INSULIN TREATMENT; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STREPTOZOCIN DIABETES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PRESSURE; CALCIMYCIN; DIABETES MELLITUS, EXPERIMENTAL; HEART RATE; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 33644779823     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.096339     Document Type: Article

References (40)

1. Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, and Wallace JL (1998) Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 62:367-373.
2. Bayraktutan U (2002) Free radicals, diabetes and endothelial dysfunction. Diabetes Obes Metab 4:224-238.
3. Carini M, Aldini G, Orioli M, and Maffei FR (2002) In vitro metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies. J Pharm Biomed Anal 29:1061-1071.
4. Carini M, Aldini G, Orioli M, Piccoli A, Rossoni G, and Maffei FR (2004) Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat. Life Sci 74:3291-3305.
5. Carini M, Aldini G, Stefani R, Orioli M, and Facino RM (2001) Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy. J Pharm Biomed Anal 26:509-518.
6. Clark C, Foreman MI, Kane KA, McDonald FM, and Parratt JR (1980) Coronary artery ligation in anesthetized rats as a method for the production of experimental dysrhythmias and for the determination of infarct size. J Pharmacol Methods 3:357-368.
7. Corazzi T, Leone M, Maucci, R, Corazzi L, and Gresele P (2005) Direct and irreversible inhibition of cyclooxygenase-1 (COX-1) by nitroaspirin (NCX 4016). J Pharmacol Exp Ther 315:1331-1337
8. De La CP, Guerrero A, Paniego J, Arranz I, Moreno A, and Sanchez DLC (2002) Effect of aspirin on prostanoids and nitric oxide production in streptozotocindiabetic rats with ischemic retinopathy. Naunyn-Schmiedeberg's Arch Pharmacol 365:96-101.
9. Del Soldato P, Sorrentino R, and Pinto A (1999) NO-aspirins: a class of new antiinflammatory and antithrombotic agents. Trends Pharmacol Sci 20:319-323.
10. Fiorucci S, Distrutti E, Mencarelli A, Rizzo G, Lorenzo AR, Baldoni M, Del Soldato P, Morelli A, and Wallace JL (2004) Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX4016) (NO-aspirin) on neutrophil-endothelial cell adherence. J Pharmacol Exp Ther 309:1174-1182.
11. Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, Hicks M, van Haperen R, de Crom, Kawashima S, Yokoyama M, et al. (2004) Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol 286:H276-H282.
12. Judge S, Mammen E, and Dunbar JC (1995) The effect of streptozocin-induced diabetes on platelet aggregation as determined by impedance aggregometry and platelet secretion: a possible role for nitric oxide. J Assoc Acad Minor Phys 6:100-104.
13. Keeble J, Al Swayeh OA, and Moore PK (2001) Vasorelaxant effect of nitric oxide releasing steroidal and nonsteroidal anti-inflammatory drugs. Br J Pharmacol 133:1023-1028.
14. Kluft C and Jesperson J (2002) Diabetes as a procoagulant condition. Br J Diabetes Vasc Dis 2:358-362.
15. Lechi C, Andrioli G, Gaino S, Tommasoli R, Zuliani V, Ortolani R, Degan M, Benoni G, Bellavite P, Lechi A, et al. (1996a) The antiplatelet effects of a new nitroderivative of acetylsalicylic acid: an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production. Thromb Haemostasis 76:791-798.
16. Lechi C, Gaino S, Tommasoli R, Zuliani V, Bonapace S, Fontana L, Degan M, Lechi A, and Minuz P (1996b) In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid. Blood Coagul Fibrinolysis 7:206-209.
17. Mehta P (2002) Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 17:552-558.
18. Minuz P, Lechi C, Tommasoli R, Gaino S, Degan M, Zuliani V, Bonapace S, Benoni G, Adami A, Cuzzolin L, et al. (1995) Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. Thromb Res 80:367-376.
19. Paulson DJ (1997) The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 34:104-112.
20. Pernow J and Wang QD (1999) The role of the L-arginine/nitric oxide pathway in myocardial ischaemic and reperfusion injury. Acta Physiol Scand 167:151-159.
21. Pieper GM, Siebeneich W, Olds CL, Felix CC, and del Soldato P (2002) Vascular protective actions of a nitric oxide aspirin analog in both in vitro and in vivo models of diabetes mellitus. Free Radic Biol Med 32:1143-1156.
22. Ravingerova T, Neckar J, Kolar F, Stetka R, Volkovova K, Ziegelhoffer A, and Styk J (2001) Ventricular arrhythmias following coronary artery occlusion in rats: is the diabetic heart less or more sensitive to ischaemia? Basic Res Cardiol 96:160-168.
23. Rossoni G, Berti M, Colonna VD, Bernareggi M, del Soldato P, and Berti F (2000) Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit. Ital Heart J 1:146-155.
24. Rossoni G, Manfredi B, Colonna VD, Bernareggi M, and Berti F (2001) The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat. J Pharmacol Exp Ther 297:380-387.
25. Schoemaker RG, Saxena PR, and Kalkman EA (1998) Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats. Cardiovasc Res 37:108-114.
26. Sheehan FH and Epstein SE (1983) Determinants of arrhythmic death during coronary artery reperfusion: effect of perfusion bed size. Am Heart J 105:911-914.
27. Takeuchi K, Ukawa H, Konaka A, Kitamura M, and Sugawa Y (1998) Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin. J Pharmacol Exp Ther 286:115-121.
28. Tashima K, Fujita A, Umeda M, and Takeuchi K (2000) Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats. Life Sci 67:1639-1652.
29. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235.
30. Verdon CP, Burton BA, and Prior RL (1995) Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite. Anal Biochem 224:502-508.
31. Verheugt FW, van der LA, Funke-Kupper AJ, Sterkman LG, Galema TW, and Roos JP (1990) Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 66:267-270.
32. Vinik A and Flemmer M (2002) Diabetes and macrovascular disease. J Diabetes Complicat 16:235-245.
33. Vivaldi MT, Kloner RA, and Schoen FJ (1985) Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am J Pathol 121:522-530.
34. Wainwright CL, Miller AM, Work LM, and del Soldato P (2002) NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. Br J Pharmacol 135:1882-1888.
35. Wainwright CL and Parratt JR (1991) Failure of cyclo-oxygenase inhibition to protect against arrhythmias induced by ischaemia and reperfusion: implications for the role of prostaglandins as endogenous myocardial protective substances. Cardiovasc Res 25:93-100.
36. Wallace JL, Muscara MN, McKnight W, Dicay M, del Soldato P, and Cirino G (1999) In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. Thromb Res 93:43-50.
37. Wanna FS, Obayashi DY, Young JN, and DeCampli WM (1995) Similtaneous manipulation of the nitric oxide and prostanoid pathway reduces myocardial reperfusion injury. J Thorac Cardiovasc Surg 110:1054-1062.
38. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, and Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568.
39. Wolfe MM, Lichtenstein DR, and Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888-1899.
40. Zhang L, Parratt JR, Beastall GH, Pyne NJ, and Furman BL (2002) Streptozotocin diabetes protects against arrhythmias in rat isolated hearts: role of hypothyroidism. Eur J Pharmacol 435:269-276.